重组人β2糖蛋白1第一结构域二聚体作为抗磷脂抗体综合征B细胞耐受原的初步探讨

J4 ›› 2009, Vol. 35 ›› Issue (4): 646-649.

重组人β2糖蛋白1第一结构域二聚体作为抗磷脂抗体综合征B细胞耐受原的初步探讨

付嘉^1,2, 谭岩¹, 方艳秋¹, 熊斌³, 徐立⁴

1.吉林大学第一医院中心实验室|吉林长春 130021；2.济宁医学院免疫学教研室|山东济宁272013；3.济宁医学院外科总论教研室|山东济宁272013；4.吉林大学第二医院检验科|吉林长春 130041

收稿日期:2008-12-30 出版日期:2009-07-28 发布日期:2009-08-24
通讯作者: 方艳秋；熊斌 E-mail:yq.fang@163.com；xiongbin1116@yahoo.cn
作者简介:付嘉（1973-）|女|黑龙江省佳木斯市人|副教授|医学博士|主要从事自身免疫病的研究。
基金资助:
吉林省科技厅杰出青年基金资助课题（20050113）；吉林省科技厅国际合作项目资助课题（20060722）；吉林省科技厅基础研究项目资助课题（200705101）

Preliminary approach on application of recombinant human |2-glycoprotein-1 domain Ⅰ dimer as B lymphocyte tolerogen

FU Jia^1,2, TAN Yan¹, FANG Yan-Qiu¹, XIONG Bin³, XU Li⁴

1.Central Laboratary,First Hospital|Jilin University,Changchun 130021,China；2. Department of Immunology,Ji’ning Medical College,Ji’ning 272013,China；3. Department of Surgery General Introduction|Ji’ning Medical College,Ji’ning 272013,China；4. Department of Laboratory,Second |Hospital|Jilin University,Changchun 130041,China

Received:2008-12-30 Online:2009-07-28 Published:2009-08-24

摘要/Abstract

摘要：

目的：探讨重组人β2糖蛋白1第一结构域二聚体（rhβ2-GP1-DⅠ₂）对重组人β2糖蛋白1（rhβ2-GP1）免疫小鼠β2-GP1特异性B细胞反应的抑制作用。方法：应用固相ELISA方法，检测静脉注射rhβ2-GP1-DⅠ₂后免疫小鼠产生的抗β2糖蛋白1抗体(anti-β2-GP1)滴度及anti-β2-GP1产生水平比率；应用ELISPOT方法，检测静脉注射rhβ2-GP1-DⅠ₂后免疫小鼠脾脏β2-GP1特异性抗体形成细胞（AFC）数量。结果：静脉注射rhβ2-GP1-DⅠ₂后，与对照组比较，rhβ2-GP1免疫小鼠βanti-β2-GP1滴度明显降低（P<0.01），anti-β2-GP1产生水平比率下降，β2-GP1特异性AFC数量明显减少（P<0.01）。结论：静脉注射rhβ2-GP1-DⅠ₂能够抑制rhβ2-GP1免疫小鼠β2-GP1特异性B细胞的反应能力。

关键词: 重组人β2糖蛋白1；第一结构域二聚体；抗磷脂抗体综合征；B细胞耐受原

Abstract:

Objective To investigate the suppression to 2-glycoprotein-1-specific B cell response by human recombinant 2-glycoprotein-1 domain Ⅰ dimer（rhβ2-GP1-DⅠ₂） in rhβ2-GP1 immunized mice. Methods The effects of treatment using rhβ2-GP1-DⅠ₂ on titer and ratio of anti-β2-GP1 were analyzed by solid phase ELISA. The number of splenic β2-GP1-specific antibody-forming cells (AFC) was counted by ELISPOT.Results The levels of anti-β2-GP1 from rhβ2-GP1 immunized mice treated with rhβ2-GP1-DⅠ₂ were significantly decreased compared with those in negative controls（P<0.01）.The reductions paralleled by decreases in ratio of anti-β2-GP1（P<0.01）；β2-GP1-specific AFC decreased at the same time（P<0.01）.
Conclusion Intravenous administration of rhβ2-GP1-DⅠ₂ could inhibit the 2-glycoprotein-1-specific B cell response in rhβ2-GP1 immunized mice.


Key words: recombinant human , 2-glycoprotein-1； domain Ⅰ dimer；anti-phospholipid antibody syndrome；B lymphocyte tolerogen

中图分类号:

R392

付嘉, 谭岩, 方艳秋, 熊斌, 徐立. 重组人β2糖蛋白1第一结构域二聚体作为抗磷脂抗体综合征B细胞耐受原的初步探讨[J]. J4, 2009, 35(4): 646-649.

FU Jia, TAN Yan, FANG Yan-Qiu, XIONG Bin, XU Li. Preliminary approach on application of recombinant human |2-glycoprotein-1 domain Ⅰ dimer as B lymphocyte tolerogen[J]. J4, 2009, 35(4): 646-649.